Older Patients Have a Better Outcome with TVR-Based Triple Therapy
Telaprevir safe, effective among older patients with chronic HCV
Furusyo N. J Hepatol. 2013;59:205-212.
July 30, 2013
Advanced age did not impact the efficacy of triple therapy with pegylated interferon, ribavirin and telaprevir among patients with hepatitis C genotype 1b in a recent study.
In a prospective study, researchers evaluated 120 patients with chronic hepatitis C genotype 1b, including 64 participants aged older than 60 years. All patients received peginterferon alfa-2b, ribavirin and telaprevir for 12 weeks, then 12 weeks of peginterferon and ribavirin. During prior therapy 53.3% of participants had relapsed, 22.5% were treatment-naive, 20.8% were prior nonresponders and 3.3% had an unknown prior response.
Continue reading this entire article:
Hepatitis C Lifestyle: Peaches Are a Great Summer Snack
Medical Update: New Perspective on Marijuana for Hepatitis C